Glutoxim therapy in improving the effectiveness of complex treatment of patients with multidrug-, pre-extensively drug- and extensively drug-resistant tuberculosis

The aim of the study was to analyse the results of adjuvant therapy with glutamyl-cysteinyl-glycine dinatrium as part of the complex treatment of patients with MDR, pre-XDR and XDR tuberculosis. Materials and methods. The results of the intensive phase of treatment of 40 patients were analysed; the first group (main) included 17 patients receiving antituberculosis chemotherapy in combination with glutamyl-cysteinyl-glycine sodium (Glutoxim), the second group (control) included 23 patients receiving only chemotherapy. Results. The study showed the effectiveness of the use of glutamyl-cysteinyl-glycine dinatrium (Glutoxim) in the form of a reduction in the elimination of intoxication symptoms and clinical manifestations, better rates of bacterial conversion (100% vs. 39.1% in the control group in the first 3 months of treatment, p<0.01) and achievement of positive radiological dynamics (100% vs. 52.2% after 4 months of treatment). The use of Glutoxime helped to reduce the frequency (17.6% in the main group vs. 43.5% in the control group, p=0.085) and duration (55.5 vs. 90 days, p=0.017) of adverse reactions to anti-TB drugs, normalisation of of liver function tests.